Revenio Group Corporation: Jouni Toijala appointed as the CEO of Revenio Group Corporation
Revenio Group Corporation, Stock Exchange Release, March 31, 2020, at 9.00 am EET
JOUNI TOIJALA APPOINTED AS THE CEO OF REVENIO GROUP CORPORATION
B.Sc., MBA Jouni Toijala, (b. 1968) has been appointed as the CEO of Revenio Group Corporation and its’ subsidiaries as of September 30th, 2020 at the latest. Timo Hildén, the long-term CEO of Revenio and Icare Finland, is committed to supporting Jouni when he takes on his role to ensure a smooth transition.
Jouni Toijala has been the CEO of Innokas Medical Oy, a provider of health technology design and manufacturing services to leading international and domestic companies since 2016. Between 2012 and 2016 he worked as the CEO of Symbio Finland Oy, a software company specializing in digital services and products. Between 1994 and 2011, he held several international management positions in France and in the UK, with Nokia Group and Meridea Financial Software UK Ltd.
Pekka Rönkä, the Chairman of the Board of Revenio Group Corporation comments:
”Jouni is a respected team player who also has a strong track record of results in leading people and developing organizations. In the recruitment process, a significant weight was put also on Jouni's experience in international business as well as in the health technology and software businesses. He is already familiar with the requirements of healthcare technology regulations and regulatory authorities, and the opportunities digitalization creates for business. Jouni's experience and skills give him an excellent ability to lead Revenio together with his team into the next phase of growth. On behalf of myself and the entire Board of Directors, I warmly welcome Jouni to the team.”
Jouni Toijala comments:
”Revenio's business is supported by strong health industry megatrends. Digitalization, data driven health care and machine learning are creating a whole new set of future opportunities for health technology companies. On the other hand, health technology regulations are increasing and becoming more complex, making it even more important for organizations to be able to navigate in a rapidly changing operating environment. Revenio is a strong grower and well-known player in the industry. I am happy and proud that I will get together with my top professional team the opportunity to develop the Group towards the next growth phase. Openly and in an atmosphere of mutual trust.”
Revenio Group Corporation
Board of Directors
For further information, please contact:
Chairman of the Board
Pekka Rönkä, puh. +358 40 826 4356
pekka.ronka@revenio.fi
Attachments:
Jouni Toijala CV and picture
DISTRIBUTION:
Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi
The Revenio Group in brief
Revenio, a health technology group operating in the international markets, is one of the global leaders in ophthalmic appliances.
The Revenio Group consists of Icare Finland Oy, Icare USA Inc., Revenio Italy S.R.L, CenterVue SpA, CenterVue Inc, Revenio Research Oy and Oscare Medical Oy.
The common denominators of Revenio's business operations include patient-oriented screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The aim is to improve the quality of life through health technology solutions which enable more effective diagnostics. Revenio Group’s focus is on the early detection of glaucoma, diabetic retinopathy and macular degeneration, and the monitoring of these during the treatment process. Revenio Research concentrates on the commercialization of systems supporting the diagnosis of and treatment planning for skin cancer and asthma.
In 2019, Revenio Group's net sales totalled EUR 49.5 million, with its net operating profit standing at 25.5%. Revenio Group Corporation is listed on Nasdaq Helsinki.
